CN Patent

CN120202010A — 配体-寡核苷酸共轭物及用于该共轭物的接头

Assigned to Shanghai Jingxin Biological Medical Co ltd · Expires 2025-06-24 · 1y expired

What this patent protects

一种配体‑寡核苷酸共轭物及用于该共轭物的接头，所述接头包含式I或II的结构：‑NR 1 ‑C(O)‑[C(R 3 R 4 )] n ‑C(O)‑[NR 2 ‑C(R a R b )‑C(O)] p ‑(式I)，或‑NR 1 ‑[C(O)‑C(R a R b )‑NR 2 ] p ‑C(O)‑[C(R 3 R 4 )] n ‑C(O)‑(式II)。该共轭物的制备方法及中间体。

USPTO Abstract

一种配体‑寡核苷酸共轭物及用于该共轭物的接头，所述接头包含式I或II的结构：‑NR 1 ‑C(O)‑[C(R 3 R 4 )] n ‑C(O)‑[NR 2 ‑C(R a R b )‑C(O)] p ‑(式I)，或‑NR 1 ‑[C(O)‑C(R a R b )‑NR 2 ] p ‑C(O)‑[C(R 3 R 4 )] n ‑C(O)‑(式II)。该共轭物的制备方法及中间体。

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: CN120202010A
Jurisdiction: CN
Classification: —
Expires: 2025-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Jingxin Biological Medical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.